Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Advancements research located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://marlong936xem9.wikilima.com/user